Importantly, this effect was observed when the antibody was administered immediately after cell engraftment (Figure 4A), but also when tumors were already established (Figure 4B), thus suggesting that anti-ErbB3 therapy may be useful both to limit CSC-induced initiation and to prevent tumor growth of established tumors. The gene discussed is ERBB3; the disease is neoplasm.